-
1
-
-
0003964361
-
-
American Cancer Society. Cancer Facts and Figures 2002. Available at: http://www.cancer.org/eprise/main/docroot/stt/stt_0. Accessed June 26, 2002.
-
(2002)
Cancer Facts and Figures 2002
-
-
-
2
-
-
0012499220
-
Recognizing prostate cancer
-
Slovin SF. Recognizing prostate cancer. Fed Practitioner 2002(Suppl);5-6.
-
(2002)
Fed Practitioner
, Issue.SUPPL.
, pp. 5-6
-
-
Slovin, S.F.1
-
3
-
-
0026444924
-
TNM classification of prostate cancer
-
Schroder FH, Hermanek P, Denis L, et al. TNM classification of prostate cancer. Prostate 1992;(Suppl)4:129-138.
-
(1992)
Prostate
, vol.4
, Issue.SUPPL.
, pp. 129-138
-
-
Schroder, F.H.1
Hermanek, P.2
Denis, L.3
-
4
-
-
0003452668
-
-
Philadelphia: Lippincott-Raven Publishers
-
th ed. Philadelphia: Lippincott-Raven Publishers; 1997.
-
(1997)
th Ed.
-
-
Fleming, I.D.1
-
5
-
-
0012499221
-
Prostate cancer staging
-
Roth BJ. Prostate cancer staging. Fed Practitioner 2002(Suppl) 9-14.
-
(2002)
Fed Practitioner
, Issue.SUPPL.
, pp. 9-14
-
-
Roth, B.J.1
-
7
-
-
0037068646
-
A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer
-
Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-789.
-
(2002)
N Engl J Med
, vol.347
, pp. 781-789
-
-
Holmberg, L.1
Bill-Axelson, A.2
Helgesen, F.3
-
8
-
-
0037068634
-
Quality of life after radical prostectomy or watchful waiting
-
Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostectomy or watchful waiting. N Engl J Med 2002; 347:790-796.
-
(2002)
N Engl J Med
, vol.347
, pp. 790-796
-
-
Steineck, G.1
Helgesen, F.2
Adolfsson, J.3
-
9
-
-
0034763168
-
Counseling the patient with prostate cancer about treatment-related erectile dysfunction
-
Montorsi F, Salonia A, Zanoni M, et al. Counseling the patient with prostate cancer about treatment-related erectile dysfunction. Curr Opin Urol 2001;11:611-617.
-
(2001)
Curr Opin Urol
, vol.11
, pp. 611-617
-
-
Montorsi, F.1
Salonia, A.2
Zanoni, M.3
-
10
-
-
0030856678
-
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
-
Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
-
(1997)
N Engl J Med
, vol.337
, pp. 295-300
-
-
Bolla, M.1
Gonzalez, D.2
Warde, P.3
-
11
-
-
85077295843
-
Triptorelin approved for prostate cancer treatment
-
Millar JL. Triptorelin approved for prostate cancer treatment. Am J Health Syst Pharm 2000;57:1386.
-
(2000)
Am J Health Syst Pharm
, vol.57
, pp. 1386
-
-
Millar, J.L.1
-
12
-
-
0031403675
-
Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial
-
The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. Br J Urol 1997;79:235-246.
-
(1997)
Br J Urol
, vol.79
, pp. 235-246
-
-
-
13
-
-
0037072063
-
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial
-
Bolla M, Collettee L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002;360:103-108.
-
(2002)
Lancet
, vol.360
, pp. 103-108
-
-
Bolla, M.1
Collettee, L.2
Blank, L.3
-
14
-
-
0036112592
-
The current state of hormonal therapy for prostate cancer
-
Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. Cancer 2002;52:154-179.
-
(2002)
Cancer
, vol.52
, pp. 154-179
-
-
Hellerstedt, B.A.1
Pienta, K.J.2
-
15
-
-
0035046991
-
The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone-releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer
-
Tomera K, Gleason D, Gittelman M, et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone-releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001;165:1585-1589.
-
(2001)
J Urol
, vol.165
, pp. 1585-1589
-
-
Tomera, K.1
Gleason, D.2
Gittelman, M.3
-
16
-
-
0001941191
-
Androgens
-
Hardman JG, Limbird LE, Molinoff PB, et al, eds. New York: McGraw-Hill
-
th ed. New York: McGraw-Hill, 1996;1441-1457.
-
(1996)
th Ed.
, pp. 1441-1457
-
-
Wilson, J.D.1
-
17
-
-
0024324367
-
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
-
Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-424.
-
(1989)
N Engl J Med
, vol.321
, pp. 419-424
-
-
Crawford, E.D.1
Eisenberger, M.A.2
McLeod, D.G.3
-
18
-
-
0034728828
-
Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials
-
Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 2000;355:1491-1498.
-
(2000)
Lancet
, vol.355
, pp. 1491-1498
-
-
-
19
-
-
0027477695
-
Prostate-specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome
-
Kelly WK, Scher HI. Prostate-specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome. J Urol 1993;149:607-609.
-
(1993)
J Urol
, vol.149
, pp. 607-609
-
-
Kelly, W.K.1
Scher, H.I.2
-
20
-
-
8444251062
-
Prostate-specific antigen (PSA) best practice policy
-
American Urological Association. Prostate-specific antigen (PSA) best practice policy. Oncology 2000;14:267-286.
-
(2000)
Oncology
, vol.14
, pp. 267-286
-
-
-
21
-
-
0034651802
-
A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma
-
Dawson NA, Conaway M, Halabi S, et al. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma. Cancer 2000;88:825-834.
-
(2000)
Cancer
, vol.88
, pp. 825-834
-
-
Dawson, N.A.1
Conaway, M.2
Halabi, S.3
-
22
-
-
0023726635
-
Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies
-
Byar DP, Corle DK Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988;7:165-170.
-
(1988)
NCI Monogr
, vol.7
, pp. 165-170
-
-
Byar, D.P.1
Corle, D.K.2
-
23
-
-
0035449137
-
Quality-of-life outcomes after primary androgen deprivation therapy: Results from the prostate cancer outcomes study
-
Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: Results from the prostate cancer outcomes study. J Clin Oncol 2001;19:3750-3757.
-
(2001)
J Clin Oncol
, vol.19
, pp. 3750-3757
-
-
Potosky, A.L.1
Knopf, K.2
Clegg, L.X.3
-
24
-
-
0034015673
-
Profile of men randomized to the prostate cancer prevention trial: Baseline health-related quality of life, urinary and sexual functioning, and health behaviors
-
Moinpour CM, Lovato LC, Thompson IM, et al. Profile of men randomized to the prostate cancer prevention trial: Baseline health-related quality of life, urinary and sexual functioning, and health behaviors. J Clin Oncol 2000;18:1942-1953.
-
(2000)
J Clin Oncol
, vol.18
, pp. 1942-1953
-
-
Moinpour, C.M.1
Lovato, L.C.2
Thompson, I.M.3
-
25
-
-
0034490101
-
Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: A decade of progress?
-
Culine S, Droz JP. Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: A decade of progress? Ann Oncol 2000;11:1523-1530.
-
(2000)
Ann Oncol
, vol.11
, pp. 1523-1530
-
-
Culine, S.1
Droz, J.P.2
-
26
-
-
0020956138
-
Weekly doxorubicin in endocrine-refractory carcinoma of the prostate
-
Torti FM, Aston D, Lum BL, et al. Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol 1983;1:477-482.
-
(1983)
J Clin Oncol
, vol.1
, pp. 477-482
-
-
Torti, F.M.1
Aston, D.2
Lum, B.L.3
-
27
-
-
0028208515
-
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer
-
Moore MJ, Osoba D, Murphy K, et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 1994;12:689-694.
-
(1994)
J Clin Oncol
, vol.12
, pp. 689-694
-
-
Moore, M.J.1
Osoba, D.2
Murphy, K.3
-
28
-
-
0031042208
-
Estramustine-based chemotherapy
-
Hudes G. Estramustine-based chemotherapy. Semin Urol Oncol 1997;15:13-19.
-
(1997)
Semin Urol Oncol
, vol.15
, pp. 13-19
-
-
Hudes, G.1
-
29
-
-
0012605521
-
-
MedWatch 2002 Safety Information. Available at: http://www.fda.gov/medwatch/safety/2002/safety02.htm. Accessed July 11, 2002.
-
(2002)
MedWatch 2002 Safety Information
-
-
-
31
-
-
0034834096
-
SELECT: The next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial
-
Klein EA, Thompson IM, Lippman SM, et al. SELECT: The next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. J Urol 2001;166:1311-1315.
-
(2001)
J Urol
, vol.166
, pp. 1311-1315
-
-
Klein, E.A.1
Thompson, I.M.2
Lippman, S.M.3
|